Omixon, Inc.
- UEI
- DW2PPM9LS8W4
- CAGE
- 7FDG5
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- omixon.com
- Founded
- 2011
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Holotype HLA 24/11 configuration and promega gotaq long PCR master mix | NIH Clinical Center | $20,445 | |
| Reagents | NIH Clinical Center | $20,445 | |
| Omixon, INC.:1264669 [23-003707] | NIH Clinical Center | $20,390 | |
| Omixon, INC.:1264669 [23-001517] | NIH Clinical Center | $20,245 | |
| Omixon, INC.:1264669 [23-000339] | NIH Clinical Center | $20,360 |
About Omixon, Inc.
Omixon, Inc. is a foreign-owned, for-profit corporation registered to receive federal contract awards from the U.S. government since August 2015. The company specializes in providing biomedical products and services related to HLA genotyping, primarily supporting research and development activities in HLA testing and transplantation. Omixon's offerings to the federal government include specialized reagents, genotyping kits, and software solutions for HLA analysis. As a molecular diagnostics company, Omixon focuses on developing and delivering advanced next-generation sequencing (NGS) technologies for HLA typing, which are crucial for various medical applications, including organ transplantation and immunological research.
The majority of Omixon's federal contract awards have come from the Department of Health and Human Services' National Institutes of Health Clinical Center. These awards have consistently involved the supply of Holotype HLA genotyping kits, specifically the 24/11 configuration, along with complementary products such as Promega GoTaq Long PCR Master Mix and HLA Twin software. Contract values have ranged from around $20,000 for individual reagent orders to larger awards exceeding $200,000 for comprehensive HLA typing solutions. All of Omixon's reported contracts have been awarded as firm fixed price purchase orders without any set-aside designations, indicating that the company competes in the open market for these specialized biomedical contracts. The consistency in both the awarding agency and the types of products supplied suggests that Omixon has established itself as a reliable provider of HLA genotyping technologies to support the NIH Clinical Center's ongoing research and clinical activities in transplantation and immunology.
SBA capabilities narrative
Research and Development in Biotechnology, In-Vitro Diagnostics, etc. Related Services, etc.
Quick answers
What is Omixon, Inc.'s UEI?
Omixon, Inc.'s Unique Entity ID (UEI) in SAM.gov is DW2PPM9LS8W4.
What is Omixon, Inc.'s CAGE code?
Omixon, Inc.'s CAGE code is 7FDG5.
What is Omixon, Inc.'s primary NAICS code?
Omixon, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Omixon, Inc. registered in SAM.gov?
Omixon, Inc.'s SAM.gov registration expired on September 12, 2026.
What is Omixon, Inc.'s most recent federal award?
Omixon, Inc.'s most recent federal contract award is Holotype HLA 24/11 configuration and promega gotaq long PCR master mix (75N90024P00135), from NIH Clinical Center, on January 9, 2024.
On GovTribe
See Omixon, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors